Table 1.
Clinical Patient Characteristics of Pediatric Medulloblastoma Patients Treated with Proton Radiotherapy
| Characteristics | N = 178 |
|---|---|
| Median follow-up (y) | 9.3 (0.5–17.2) |
| Age at RT (y) | 8.1 (2.5–24.1) |
| ≤8 Y | 88 (49.4) |
| >8 Y | 90 (50.6) |
| Gender | |
| Male | 103 (57.9) |
| Female | 75 (42.1) |
| Histological subtype | |
| Classic and or desmoplastic | 152 (85.4) |
| Anaplastic or large cell variant | 26 (14.6) |
| Extent of resection | |
| GTR/near-GTR | 159 (89.3) |
| STR | 18 (10.1) |
| Biopsy only | 1 (0.6) |
| Risk | |
| Standard risk | 102 (57.3) |
| Intermediate | 16 (9.0) |
| High risk | 60 (33.7) |
| Chemotherapy | |
| No | 0 (0) |
| Yes | 178 (100.0) |
| Chemo timing | |
| Prior | 29 (16.3) |
| During | 139 (78.1) |
| After | 73 (41.0) |
| Modality | |
| PBS | 7 (3.9) |
| Passive scatter | 170 (95.5) |
| Both | 1 (0.6) |
| Craniospinal radiation dose (GyRBE)a | 23.4 (18.0–36.0) |
| 18.0 to <23.4 | 8 (4.6) |
| 23.4 | 107 (61.1) |
| >23.4 to <36.0 | 13 (7.4) |
| 36.0 | 47 (26.9) |
| Stage | |
| M0 | 131 (73.6) |
| M1 | 5 (2.8) |
| M2 | 16 (9.0) |
| M3 | 26 (14.6) |
| Total dose | 54 (50.4–59.4) |
| ≤ 54 | 170 (95.5) |
| > 54 | 8 (4.5) |
| Surgery to RT interval (days) | 32.0 (18.0–662.0) |
| ≤ 35 Days | 97 (54.5) |
| >35 Days | 81 (45.5) |
| Median radiation treatment time in days (range) | 42.0 (21.0–51.0) |
| ≤ 45 Days | 151 (84.8) |
| >45 Days | 27 (15.2) |
Abbreviations: CSI, cranio-spinal irradiation; GTR, gross total resection; GyRBE, gray relative biological equivalents; PBS, pencil beam scanning; RT, radiotherapy; STR, subtotal resection.
aExcludes 3 who did not receive CSI.